Final recommendation from NICE on Simponi for ankylosing spondylitis
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has issued final guidance recommending Merck & Co's subcutaneous anti-TNF-alpha monoclonal antibody Simponi (golimumab) as a treatment option for ankylosing spondylitis. But as described in earlier draft guidance, there are certain conditions attached to the recommendation (scripintelligence.com, 24 June 2011).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.